AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIIA Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Classic Hodgkin Lymphoma, HIV Infection
Conditions
Brief summary
This pilot phase I/II trial studies the side effects and the best dose of brentuximab vedotin when given together with combination chemotherapy and to see how well they work in treating patients with stage II-IV human immunodeficiency virus (HIV)-associated Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a chemotherapy drug called vedotin. Brentuximab attaches to CD30-positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin together with combination chemotherapy may kill more cancer cells.
Detailed description
PRIMARY OBJECTIVES I. To identify the maximum tolerated dose (MTD) of brentuximab vedotin when combined with the doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD) chemotherapy regimen in the treatment of HIV-associated stage II-IV Hodgkin lymphoma. (Phase I) II. Establish an estimate of the two-year progression-free survival (PFS) for participants with HIV-associated stage II-IV Hodgkin lymphoma when treated using brentuximab vedotin plus the AVD chemotherapy regimen. (Phase II) SECONDARY OBJECTIVES: I. To evaluate the toxicity of AVD and brentuximab vedotin with highly active antiretroviral therapy (HAART). II. To estimate the partial response (PR) rate, complete response (CR) rate, overall survival (OS), and event free survival (EFS) at 2 and 5 years. III. To evaluate the effect of AVD and brentuximab vedotin on cluster of differentiation (CD)4 and CD8 counts after cycle 1, 4, at the end of therapy, and every 3 months after treatment completion for one year. IV. To investigate the prognostic value of fludeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scans at baseline, after cycle 2, and at treatment completion, with respect to 2-year progression free survival. V. To evaluate HAART status at baseline and to correlate this with tumor response to therapy and OS and PFS. VI. To characterize the histologic subtypes in HIV-Hodgkin lymphoma (HL) in the highly active antiretroviral therapy (HAART) era. VII. To assess the neurotoxicity of HAART in combination with AVD and brentuximab vedotin. VIII. To evaluate effect of AVD and brentuximab vedotin on viral load after cycles 1, 4, at the completion of therapy, and every 3 months after treatment completion for one year. IX. To perform pharmacokinetic and immunogenicity studies to determine drug levels during therapy. X. To perform micro ribonucleic acid (miRNA) profile analysis on the HIV-HL tumor specimens and to correlate miRNA expression with OS, PFS, tumor response to therapy, histologic subtype of HIV-HL, and HIV disease characteristics. XI. To perform tissue microarray analysis on HIV-HL tumor specimens and to correlate the markers studied with OS, PFS, and tumor response to therapy. XII. To identify Epstein-Barr virus (EBV)-associated tumor derived deoxyribonucleic acid (DNA) in the plasma of study participants and to correlate these levels during therapy with disease response and OS. (Phase II) XIII. To identify cytokines in the plasma of participants during therapy that can be used as tumor and prognostic markers. (Phase II) XIV. To assess latent and expressed HIV reservoirs before, during, and post chemotherapy. To understand how cytotoxic chemotherapeutic agents affect HIV expression. OUTLINE: This is a phase I, dose-escalation study of brentuximab vedotin followed by a phase II study. Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Interventions
DRUGBrentuximab Vedotin
Given IV
DRUGDacarbazine
Given IV
DRUGDoxorubicin Hydrochloride
Given IV
OTHERPharmacological Study
Correlative studies
DRUGVinblastine
Given IV
Sponsors
The Lymphoma Academic Research Organisation
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV positive; documentation of HIV-1 infection by means of any one of the following: * Documentation of HIV diagnosis in the medical record by a licensed health care provider; * Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider; * HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating \> 1000 RNA copies/mL; * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay * NOTE: A licensed assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies * Histologic diagnosis of CD30-positive classical HL as defined by the 2008 World Health Organization (WHO) Classification of Hematological diseases; nodular lymphocyte predominant Hodgkin lymphoma is not eligible * Stage II, III or IV disease as defined by the Ann Arbor Staging System * Participants must have previously untreated HIV-classical HL (cHL), with the exception of up to 14 consecutive days of steroids, emergency radiation, or 1 prior cycle of cyclophosphamide to reduce tumor burden and improve hyperbilirubinemia in the setting of lymphoma related liver involvement * Normal baseline cardiac ejection fraction \>= 50% * Serum creatinine of =\< 1.5 mg/dL; if creatinine \> 1.5 mg/dL, creatinine clearance must be \>= 60 mL/minute * Absolute neutrophil count (ANC) \>= 1000/uL * Platelets \>= 75,000/uL unless related to bone marrow involvement by HIV-cHL * Total bilirubin must be \< 1.5 x the upper limit of normal, unless the elevation of bilirubin is thought to be secondary to Gilbert's syndrome or combined antiretroviral therapy (cART); if, however, the elevated bilirubin is felt to be secondary to antiretroviral therapy, the total bilirubin must be =\< 3.5 mg/dL, provided that the direct bilirubin is normal and the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x the upper limit of normal; also, if the elevated bilirubin is thought to be secondary to cHL the same criteria for hyperbilirubinemia should be applied; however 1 prior cycle of cyclophosphamide is permitted in attempt to make the participant eligible; patients should not be excluded from study participation unless dosing cannot be safely established * Female participants must have a negative pregnancy test within 1 week of enrollment and all participants must agree to use two reliable methods of contraception simultaneously if conception is possible during the study and for 6 months after stopping treatment; should a woman subject become pregnant or suspect she is pregnant while the subject is participating in this study, she should inform her treating physician immediately; the participant will then be removed from protocol therapy; participants who father a child while participating in the study will be permitted to continue with the protocol; the participant, however, is required to notify the investigator if he fathers a child * Ability to understand and the willingness to sign a written informed consent document * Karnofsky performance status \> 30% (given the aggressiveness of this disease and the often severely debilitated nature of the patients at initial presentation) * Measurable or non-measurable (evaluable) tumor parameter(s); non-measurable tumor parameters will be defined as not having bi-dimensional measurements (i.e., gastric or marrow involvement) but can be followed for response by other diagnostic tests such as gallium, PET imaging and/or bone marrow biopsy * Patients already receiving erythropoietin or granulocyte colony stimulating factor (GCSF) for treatment of HIV-related cytopenia are eligible * CD4 count \>= 50 cells/ul * Participants are required to be on antiretroviral regimens that are in accordance with the current International Acquired Immune Deficiency Syndrome (AIDS) Society guidelines concurrently with chemotherapy; the specific agents are at the discretion of the investigator and the use of investigational agents currently available on an expanded access basis is allowed; use of experimental antiretroviral agents or those containing zidovudine (including Combivir and Trizivir) or ritonavir (includes Norvir or Kaletra), cobicistat, didanosine (Videx or Videx EC), or similar potent cytochrome P450 (CYP)3 inhibitors are prohibited; in order to be eligible, participants taking zidovudine or ritonavir, or cobicistat, didanosine, or other CYP3 inhibitors must change to a different regimen 7 days prior to therapy initiation; changes to HAART therapy during the study may be made if medically necessary (toxicity, failure of regimen, etc.); participants must be on HAART at least 7 days prior to therapy * Negative for hepatitis B, or if infected with hepatitis B, receiving anti-hepatitis B therapy; all participants will be required to be screened for hepatitis B; per Infectious Disease Society of America (IDSA) and Assistance for AIDS Specific Drugs (AASD) guidelines, those participants that show no immunity, defined by the lack of hepatitis B surface antigen antibody, and show evidence of chronic infection (i.e. hepatitis B surface antigen \[HBsAg\]+, hepatitis B core \[HBcore\]+, hepatitis B surface antibody \[HBsAB\]-) will be required to be on anti-hepatitis B therapy during the study in order to be eligible; patients will be permitted to enroll in the study provided normal liver function tests and no evidence of cirrhosis; the exact hepatitis B therapy will be at the discretion of the infection disease specialist or investigator; however all patients who present with acute hepatitis B or show normal transaminases and are hepatitis B virus HBsAg surface protein antigen (HBsAg) positive (+) and immunoglobulin M (IgM)+ for hepatitis core antigen will not be eligible for trial enrollment * Patients diagnosed with hepatitis C who are hepatitis C antibody positive, whether hepatitis C RNA level is measurable or not, must have no evidence of cirrhosis and have liver function tests * Brentuximab vedotin is partially metabolized via the CYP3A4 pathway and is cleared from the cells via the P-glycoprotein pump; therefore, participants must discontinue use of the following agents within 7 days prior to therapy * Strong CYP3A4 inhibitors that treat HIV * Other strong CYP3A inhibitors * Moderate CYP3A4 inhibitors should be used with caution but are not excluded; if 2 moderate CYP3A4 inhibitors are used concurrently, one must be discontinued at least 7 days (1 week) prior to the initiation of chemotherapy * P-glycoprotein inhibitors * If patients are taking any of these excluded medications, they must be discontinued at least 7 days (1 week) prior to the initiation of chemotherapy All concomitant medications must be reviewed by the study chair or co-chair prior to enrollment by email; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of
Exclusion criteria
* Patients with prior anthracycline therapy will be excluded * Female participants who are pregnant or breast-feeding; confirmation that the subject is not pregnant must be established by a negative serum beta (b)-human chorionic gonadotropin (b-hCG) or urine pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women * Medical illness unrelated to HL, which in the opinion of the study physician will preclude administration of chemotherapy safely; this includes patients with uncontrolled infection (including opportunistic), chronic renal failure, myocardial infarction (MI) within the past 6 months, unstable angina, or cardiac arrhythmias other than chronic atrial fibrillation, or second malignancy requiring active treatment * Prior malignancy within 2 years before enrollment other than curatively treated cutaneous basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, anal intraepithelial neoplasia, or cutaneous Kaposi's sarcoma (KS); participants with prior malignancies must have completed all therapy at least 2 years before enrollment with no evidence of disease since therapy completion * Grade 2 or greater peripheral neuropathy * Evidence of progressive multifocal leukoencephalopathy (PML) identified on the pretreatment magnetic resonance imaging (MRI) * Central nervous system disease * Patients with history of John Cunningham (JC) virus identified in the cerebrospinal fluid (CSF) or previous history of PML will be excluded from the study * Cirrhosis secondary to any cause will be excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) | 28 days | Defined as the dose level at which =\< 1 of 6 subjects experience dose limiting toxicity. |
| 2-year Progression-free Survival (PFS) (Phase II) | 2 years | 2-year PFS is determined based on the Kaplan-Meier estimates and corresponding 95% confidence intervals based on standard errors using Greenwood's formula. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Adverse Events | Up to 5 years | Number of Participants who had one or more adverse events |
| Partial Response Rate | 2 years | Number of participants who achieved a partial response per RECIST v1.0 criteria |
| Complete Response Rate | 2 years | Number of participants who experienced a complete response per RECIST v1.0 criteria |
| 2-year Overall Survival | 2 years | Proportion of study participants who are alive at 2 years estimated using the Kaplan-Meier survival function |
| Overall Survival | 5 years | Proportion of participants who are alive at 5 years using a Kaplan-Meier estimate |
| Event-free Survival | 2 years | Proportion of participants who are alive and progression-free at 2 years |
| CD8 Counts | 5 months | Absolute CD8 counts at cycle 5 |
| Prognostic Value of Fludeoxyglucose F-18 (FDG)-Positron Emission Tomography (PET) in Patient With HIV and Hodgkin Lymphoma (HL) With Respect to 2 Year Progression Free Survival | Baseline up to 2 years | Log-rank analysis will be used to investigate the prognostic value of FDG-PET scans at baseline, after 2 courses and post-therapy in patients with HIV and HL with respect to progression free survival. |
| Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival | Baseline up to 2 years | Log-rank analysis will be used to investigate the prognostic value of FDG-PET scans at baseline, after 2 courses and post-therapy in patients with HIV and HL with respect to progression free survival. |
| HAART Status | Baseline up to 2 years | Log-rank analysis will be used to evaluate HAART status at baseline for difference in outcome in terms of progression free survival at 2 years. |
| Characterization of Histologic Subtypes in HIV-HL in the HAART Era | Baseline | Participants with mixed cellularity histologic subtype in HIV-HL in the HAART era |
| Incidence of Neurotoxicity | 5 months | Number of participants who experience neurotoxicity at cycle 5 (visit 4) |
| CD4 Counts | 5 months | CD4 counts (absolute) at visit 4 (cycle 5) |
| Viral Load | 5 months | HIV viral load (detectable) |
Countries
France, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Phase I - Brentuximab 1.2 mg/kg Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Brentuximab Vedotin: Given IV
Dacarbazine: Given IV
Doxorubicin Hydrochloride: Given IV
Pharmacological Study: Correlative studies
Vinblastine: Given IV | 6 |
| Phase II - Brentuximab 1.2 mg/kg Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Brentuximab Vedotin: Given IV
Dacarbazine: Given IV
Doxorubicin Hydrochloride: Given IV
Pharmacological Study: Correlative studies
Vinblastine: Given IV | 35 |
| Total | 41 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 3 |
| Overall Study | Lost to Follow-up | 0 | 1 |
| Overall Study | Other | 0 | 1 |
| Overall Study | participant moved | 0 | 1 |
| Overall Study | Withdrawal by Subject | 0 | 2 |
Baseline characteristics
| Characteristic | Phase I - Brentuximab 1.2 mg/kg | Total | Phase II - Brentuximab 1.2 mg/kg |
|---|---|---|---|
| Age, Continuous | 38.5 years STANDARD_DEVIATION 12.2 | 43.4 years STANDARD_DEVIATION 12 | 44.3 years STANDARD_DEVIATION 12 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 9 Participants | 9 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 21 Participants | 16 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 11 Participants | 10 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 11 Participants | 10 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 12 Participants | 11 Participants |
| Race (NIH/OMB) White | 4 Participants | 18 Participants | 14 Participants |
| Region of Enrollment France | 0 participants | 9 participants | 9 participants |
| Region of Enrollment United States | 6 participants | 32 participants | 26 participants |
| Sex: Female, Male Female | 1 Participants | 3 Participants | 2 Participants |
| Sex: Female, Male Male | 5 Participants | 38 Participants | 33 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 3 / 35 |
| other Total, other adverse events | 6 / 6 | 34 / 35 |
| serious Total, serious adverse events | 3 / 6 | 16 / 35 |
Outcome results
Primary
2-year Progression-free Survival (PFS) (Phase II)
2-year PFS is determined based on the Kaplan-Meier estimates and corresponding 95% confidence intervals based on standard errors using Greenwood's formula.
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | 2-year Progression-free Survival (PFS) (Phase II) | 1.0 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | 2-year Progression-free Survival (PFS) (Phase II) | 0.878 proportion of participants |
Primary
Maximal Tolerated Dose of Brentuximab Vedotin (Phase I)
Defined as the dose level at which =\< 1 of 6 subjects experience dose limiting toxicity.
Time frame: 28 days
Population: Participants entered into the phase I portion of the study
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) | 1.2 mg/kg |
Secondary
2-year Overall Survival
Proportion of study participants who are alive at 2 years estimated using the Kaplan-Meier survival function
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | 2-year Overall Survival | 1.0 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | 2-year Overall Survival | 0.91 proportion of participants |
Secondary
CD4 Counts
CD4 counts (absolute) at visit 4 (cycle 5)
Time frame: 5 months
Population: Participants with absolute cd4 counts at cycle 5
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | CD4 Counts | 378 cells/µL |
| Phase II - Brentuximab 1.2 mg/kg | CD4 Counts | 401 cells/µL |
Secondary
CD8 Counts
Absolute CD8 counts at cycle 5
Time frame: 5 months
Population: Participants with absolute CD8 counts at cycle 5
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | CD8 Counts | 719.5 cells/µL |
| Phase II - Brentuximab 1.2 mg/kg | CD8 Counts | 666.5 cells/µL |
Secondary
Characterization of Histologic Subtypes in HIV-HL in the HAART Era
Participants with mixed cellularity histologic subtype in HIV-HL in the HAART era
Time frame: Baseline
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Characterization of Histologic Subtypes in HIV-HL in the HAART Era | 2 Participants |
| Phase II - Brentuximab 1.2 mg/kg | Characterization of Histologic Subtypes in HIV-HL in the HAART Era | 13 Participants |
Secondary
Complete Response Rate
Number of participants who experienced a complete response per RECIST v1.0 criteria
Time frame: 2 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Complete Response Rate | 6 Participants |
| Phase II - Brentuximab 1.2 mg/kg | Complete Response Rate | 32 Participants |
Secondary
Complete Response Rate
Number of participants who achieved a complete response per RECIST v1.0 criteria
Time frame: 5 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Complete Response Rate | 6 Participants |
| Phase II - Brentuximab 1.2 mg/kg | Complete Response Rate | 33 Participants |
Secondary
Event-free Survival
Binomial probabilities and their 95% confidence intervals will be used to estimate the response rates (i.e., partial response rate, complete response rate, overall response rate) and event free survival at 2 and 5 years of AVD and brentuximab vedotin for a treatment of patients with stage III/IV HIV-associated Hodgkin lymphoma.
Time frame: 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Event-free Survival | 1.0 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | Event-free Survival | 0.743 proportion of participants |
Secondary
Event-free Survival
Proportion of participants who are alive and progression-free at 2 years
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Event-free Survival | 1.0 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | Event-free Survival | 0.878 proportion of participants |
Secondary
Frequency of Adverse Events
Number of Participants who had one or more adverse events
Time frame: Up to 5 years
Population: Participants who were treated with brentuximab and combination chemotherapy
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Frequency of Adverse Events | 6 Participants |
| Phase II - Brentuximab 1.2 mg/kg | Frequency of Adverse Events | 35 Participants |
Secondary
HAART Status
Log-rank analysis will be used to evaluate HAART status at baseline for difference in outcome in terms of progression free survival at 2 years.
Time frame: Baseline up to 2 years
Population: All participants had HAART at baseline. Logrank test cannot be performed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | HAART Status | HAART yes | 1.0 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | HAART Status | HAART yes | 0.878 proportion of participants |
Secondary
HAART Status
Log-rank analysis will be used to evaluate HAART status at baseline for difference in outcome in terms of overall survival at 2 years.
Time frame: Baseline up to 2 years
Population: All participant had HAART at baseline. Logrank test cannot be performed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | HAART Status | HAART yes | 1.0 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | HAART Status | HAART yes | 0.911 proportion of participants |
Secondary
Incidence of Neurotoxicity
Number of participants who experience neurotoxicity at cycle 5 (visit 4)
Time frame: 5 months
Population: Participants who had neurotoxicity evaluated at cycle 5
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Incidence of Neurotoxicity | 4 Participants |
| Phase II - Brentuximab 1.2 mg/kg | Incidence of Neurotoxicity | 23 Participants |
Secondary
Overall Survival
Proportion of participants who are alive at 5 years using a Kaplan-Meier estimate
Time frame: 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Overall Survival | 1.0 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | Overall Survival | 0.876 proportion of participants |
Secondary
Partial Response Rate
Number of participants who achieved a partial response per RECIST v1.0 criteria
Time frame: 2 years
Population: Patients who completed therapy
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Partial Response Rate | 1 Participants |
| Phase II - Brentuximab 1.2 mg/kg | Partial Response Rate | 4 Participants |
Secondary
Partial Response Rate
Number of participants who achieved a partial response per RECIST v1.0 criteria
Time frame: 5 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Partial Response Rate | 0 Participants |
| Phase II - Brentuximab 1.2 mg/kg | Partial Response Rate | 0 Participants |
Secondary
Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival
Log-rank analysis will be used to investigate the prognostic value of FDG-PET scans at baseline, after 2 courses and post-therapy in patients with HIV and HL with respect to progression free survival.
Time frame: Baseline up to 2 years
Population: PET-CT positive status was used within each arm.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival | PET-CT positive | 1.0 proportion of participants |
| Treatment (Brentuximab and Combination Chemotherapy) | Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival | PET-CT negative | 1.0 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival | PET-CT positive | 1.0 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival | PET-CT negative | 0.897 proportion of participants |
Secondary
Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival
Log-rank analysis will be used to investigate the prognostic value of FDG-PET scans at baseline, after 2 courses and post-therapy in patients with HIV and HL with respect to progression free survival.
Time frame: Baseline up to 2 years
Population: PET-CT positive status was used within each arm.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival | PET-CT negative | 1.0 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival | PET-CT positive | 1.0 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | Prognostic Value of FDG-PET in Patient With HIV and HL With Respect to 2 Year Progression Free Survival | PET-CT negative | 0.92 proportion of participants |
Secondary
Prognostic Value of Fludeoxyglucose F-18 (FDG)-Positron Emission Tomography (PET) in Patient With HIV and Hodgkin Lymphoma (HL) With Respect to 2 Year Progression Free Survival
Log-rank analysis will be used to investigate the prognostic value of FDG-PET scans at baseline, after 2 courses and post-therapy in patients with HIV and HL with respect to progression free survival.
Time frame: Baseline up to 2 years
Population: PET-CT positive status was used within each arm.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Prognostic Value of Fludeoxyglucose F-18 (FDG)-Positron Emission Tomography (PET) in Patient With HIV and Hodgkin Lymphoma (HL) With Respect to 2 Year Progression Free Survival | PET-CT positive | 0.876 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | Prognostic Value of Fludeoxyglucose F-18 (FDG)-Positron Emission Tomography (PET) in Patient With HIV and Hodgkin Lymphoma (HL) With Respect to 2 Year Progression Free Survival | PET-CT positive | 0.876 proportion of participants |
| Phase II - Brentuximab 1.2 mg/kg | Prognostic Value of Fludeoxyglucose F-18 (FDG)-Positron Emission Tomography (PET) in Patient With HIV and Hodgkin Lymphoma (HL) With Respect to 2 Year Progression Free Survival | PET-CT negative | 0 proportion of participants |
Secondary
Viral Load
HIV viral load (detectable)
Time frame: 5 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Brentuximab and Combination Chemotherapy) | Viral Load | 1 Participants |
| Phase II - Brentuximab 1.2 mg/kg | Viral Load | 7 Participants |